Please Note:
This profile was automatically generated using 2 references found on the Internet. This information has not been verified. Learn more...
This profile was automatically generated using 2 references found on the Internet. This information has not been verified. Learn more...
Employment History
View...Web References
-
1. QUARK BIOTECH APPOINTS DR. JAMES SHOOK AND DR. IHOR BEKERSKY TO DRUG DEVELOPMENT TEAM
www.noonanrusso.com/news/view_ - [Cached]Published on: 9/4/2002 Last Visited: 8/25/2003
Cleveland, OH September 04, 2002- Quark Biotech announced today the appointment of James Shook, Ph.D., to Executive Vice President of Product Development and Ihor Bekersky, Ph.D., to Vice President of Clinical Development.
...
Dr. Ihor Bekersky will oversee the preclinical evaluation and testing of drug candidates emerging from Quark's drug discovery programs. He brings to Quark over 25 years of pharmaceutical and biotechnology experience, including more than a decade each at Hoffmann-La Roche and Fujisawa Healthcare Inc. His expertise encompasses ADME/Toxicology and clinical pharmacology studies needed for submission of INDs and NDAs and he has been involved in decision-making regarding policies for global drug development. Dr. Bekersky received his Ph.D. in Biochemistry from New York University. -
2. QUARK BIOTECH APPOINTS DR. JAMES SHOOK AND DR. IHOR BEKERSKY TO DRUG DEVELOPMENT TEAM
www.nrp-euro.com/news/view_new - [Cached]Published on: 9/4/2002 Last Visited: 9/2/2003
Cleveland, OH September 04, 2002- Quark Biotech announced today the appointment of James Shook, Ph.D., to Executive Vice President of Product Development and Ihor Bekersky, Ph.D., to Vice President of Clinical Development.
...
Dr. Ihor Bekersky will oversee the preclinical evaluation and testing of drug candidates emerging from Quark's drug discovery programs. He brings to Quark over 25 years of pharmaceutical and biotechnology experience, including more than a decade each at Hoffmann-La Roche and Fujisawa Healthcare Inc. His expertise encompasses ADME/Toxicology and clinical pharmacology studies needed for submission of INDs and NDAs and he has been involved in decision-making regarding policies for global drug development. Dr. Bekersky received his Ph.D. in Biochemistry from New York University.
